Court rejects FDA pre-emption claims
Executive Summary
In a June 22 ruling in a case involving Wyeth's Prempro (estrogen/progestin), New Jersey Superior Court rules that FDA approval of a drug's label is insufficient to pre-empt a product liability suit claiming inadequate warning of the product's risks. The Third Circuit U.S. Court of Appeals is set to be the first appellate court to address preemption with two pending cases (1"The Pink Sheet" April 9, 2007, p. 24)...
You may also be interested in...
FDA Preemption Policy Gets First Appeals Court Test With Zoloft, Paxil Cases
A federal appellate court will take up the issue of whether FDA approved labeling preempts state litigation claiming companies failed to warn of a product's risks, following years of conflicting rulings from district courts
Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: